Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Impression: stay on the sidelines until P2s come out, preferably from IMGN901... nothing moving the needle until next year (T-DM1 P3 results, P2 results from IMGN901...) … Could possibly dip more, not buying unless it goes under 500m cap. Not worth a billion now, theyve got nothing except meager earnings from T-DM1 to rely on.

-P3 results in mid 2012, followed by FDA application
- get 10-15m if they pass P3, “mid single digits” of sales
- 5 percent of a billion sales = 50 mill. This is probably a conservative estimate as pointed out in previous guesstimates of sales prices.

-in P2 with Sanofi this year, P1 showed 33% response rate for relapse/refractory NHL

About B-cell Non-Hodgkin's Lymphoma
B-cell lymphomas comprise approximately 85% of non-Hodgkin's lymphomas in the United States and account for about 4% of all cancers. In 2010, over 65,000 people will be diagnosed with NHL and 20,000 people will die from it. The 5-year survival rate for this disease is around 67%

-myeloma, SCLC, ovarian CA, merkel cell (on hold for MCC)
-60% of myeloma had objective response, all had prior tx, 2/3 had 3 or more
-wholly owned
-expect data for SCLC P2 in 2H2012

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.